WALTHAM, Massachusetts--(BUSINESS WIRE)--Avedro Inc., a Boston‐based ophthalmic medical device and pharmaceutical company, today announced it will present at the Cowen and Company 34th Annual Health Care Conference in Boston on March 4th. David Muller, Chief Executive Officer, will discuss the company in a presentation scheduled to begin at 9:00 a.m. ET.
About Avedro, Inc.
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross‐linking and refractive correction. Avedro’s products include capital equipment and related single dose pharmaceuticals. Those products are currently used in a procedure known as Lasik Xtra®. Over 70,000 procedures have been successfully performed outside the US using Avedro’s KXL® System. The KXL System’s accelerated cross‐linking, in combination with its pharmaceuticals, is also used to treat several important and debilitating ophthalmic pathologies outside the United States.
Avedro distributes its products in 62 countries through 33 ophthalmic distributors with 115 representatives. Avedro products that have received CE Mark include: the KXL II™ System for performing PiXL™, the KXL System for performing Lasik Xtra and Accelerated Cross‐linking, and the Avedro family of proprietary single dose pharmaceutical formulations.
Avedro’s KXL System and single dose pharmaceutical products are currently being used in three Phase III US clinical trials involving over 100 US clinical sites. Avedro products are not for sale in the US.